Breast Neoplasms

• EMA approval · 2026-02-03
  EMA Authorised: Trazimera (trastuzumab) — Pfizer Europe MA EEIG

  The EMA has authorised Trazimera (trastuzumab) for stomach and breast neoplasms, with Pfizer Europe MA EEIG as the marketing authorization h…

• EMA approval · 2026-01-06
  EMA Authorised: Tyverb (lapatinib) — Novartis Europharm Limited

  The European Medicines Agency has authorised Tyverb (lapatinib) for breast neoplasms. The marketing authorisation holder is Novartis Europha…

• EMA approval · 2025-12-03
  EMA Authorised: Enhertu (trastuzumab deruxtecan) — Daiichi Sankyo Europe GmbH

  The EMA authorised Enhertu (trastuzumab deruxtecan) for breast neoplasms with conditional approval, issued to Daiichi Sankyo Europe GmbH; de…

• EMA approval · 2025-11-27
  EMA Authorised: Lynkuet (elinzanetant) — Bayer AG

  The European Medicines Agency authorised Lynkuet (elinzanetant) from Bayer AG for menopausal symptoms including hot flashes and indications …

• EMA approval · 2025-07-11
  EMA Authorised: Capecitabine Teva (capecitabine) — Teva Pharma B.V.

  EMA authorised Capecitabine Teva (capecitabine), a generic capecitabine product by Teva Pharma B.V., for multiple cancer indications, includ…

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
• EMA approval · 2024-10-11
  EMA Authorised: Halaven (Eribulin) — Eisai GmbH

  The EMA authorised Halaven (eribulin) for breast neoplasms and liposarcoma under Eisai GmbH, with a decision date of 26 July 2024.

• EMA approval · 2024-08-28
  EMA Authorised: Ibandronic Acid Teva (ibandronic acid) — Teva Pharma B.V.

  EMA authorised Teva's ibandronic acid with indications including postmenopausal osteoporosis, breast neoplasms, neoplasm metastasis, and bon…

• EMA approval · 2022-07-06
  EMA Authorised: Ibandronic Acid Sandoz (ibandronic acid) — Sandoz GmbH

  The EMA authorised Ibandronic Acid Sandoz (ibandronic acid) for indications including breast neoplasms, neoplasm metastasis, and fractures d…